Overview

Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma

Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a three parallel cohort, open-labeled, non-randomized, multicenter study. All three cohorts will enroll independently.
Phase:
Phase 1
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Collaborator:
Tragara Pharmaceuticals, Inc.
Treatments:
Temozolomide